Notice of the National Institute on Drug Abuse(NIDA) Participation in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)"

Notice Number: NOT-DA-15-045

Key Dates
Release Date:  February 24, 2015  

Related Announcements
PAR-15-070

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PAR-15-070 "Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)"

The following sections of PAR-15-070 have been updated to reflect NIDA's participation in this funding opportunity announcement.

Part 1.  Overview Information

Components of Participating Organizations
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.853, 93.279

Part 2. Section VII. Agency Contacts

Scientific/Research Contact
Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: boughk@mail.nih.gov

Financial/Grants Management Contact
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8729
Email: pfleming@nida.nih.gov 

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: boughk@mail.nih.gov